Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Argadin is a cyclic pentapeptide natural product and a member of the oligopeptide class, with the chemical formula C29H42N10O9 and molecular weight approximately 674.7 Da[1][3][9]. It was originally isolated from the cultured broth of a fungal strain identified as Clonostachys sp. FO-7314[4]. Argadin acts as a potent nanomolar inhibitor of Family-18 chitinases, specifically inhibiting chitinase B (ChiB) with a Ki value of about 20 nM[2][3]. Chitinases are enzymes involved in the degradation of chitin, an essential component in fungal cell walls and some parasites. Due to its mechanism, argadin has been investigated primarily for research purposes related to anti-infective activity and as an experimental tool for studying chitinase function[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on argadin.